Anti-body Drug Approved for Classical Hodgkin Lymphoma
Adcetris is an antibody-drug conjugate, that consists of the chimeric monoclonal antibody brentuximab connected via linkers to the antimitotic (an agent that stops cell division) known as monomethyl auristatin E / MMAE. Vedotin refers to MMAE plus its linking structure. The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate, Adcetris as a first-line treatment in stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer